Analysts Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target at $16.07

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been given an average rating of “Moderate Buy” by the seven analysts that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $16.07.

Several research analysts recently commented on MRNS shares. StockNews.com downgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $3.00 target price (down from $24.00) on shares of Marinus Pharmaceuticals in a research note on Monday, April 15th. Robert W. Baird reaffirmed a “neutral” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. Finally, Oppenheimer reaffirmed a “market perform” rating and issued a $9.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th.

Marinus Pharmaceuticals Trading Up 4.1 %

Shares of MRNS stock opened at $1.51 on Friday. The business has a 50-day moving average price of $6.69 and a two-hundred day moving average price of $7.96. Marinus Pharmaceuticals has a 12-month low of $1.11 and a 12-month high of $11.26. The company has a quick ratio of 4.01, a current ratio of 4.07 and a debt-to-equity ratio of 5.68. The firm has a market cap of $82.94 million, a P/E ratio of -0.57 and a beta of 1.14.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). The firm had revenue of $7.19 million during the quarter, compared to the consensus estimate of $7.78 million. Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. During the same quarter in the previous year, the firm earned ($0.76) EPS. Equities analysts anticipate that Marinus Pharmaceuticals will post -2.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. BluePath Capital Management LLC purchased a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth about $38,000. China Universal Asset Management Co. Ltd. grew its position in shares of Marinus Pharmaceuticals by 383.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 5,003 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Marinus Pharmaceuticals in the 4th quarter worth about $134,000. Sherbrooke Park Advisers LLC bought a new position in Marinus Pharmaceuticals in the 3rd quarter worth about $141,000. Finally, Acuta Capital Partners LLC bought a new position in Marinus Pharmaceuticals in the 3rd quarter worth about $157,000. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.